What is Zacks Research’s Estimate for Stryker Q1 Earnings?

Stryker Co. (NYSE:SYK) – Stock analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Stryker in a research report issued to clients and investors on Monday, November 18th. Zacks Research analyst I. Bandyopadhyay now expects that the medical technology company will post earnings of $2.82 per share for the quarter, up from their previous estimate of $2.74. The consensus estimate for Stryker’s current full-year earnings is $12.06 per share. Zacks Research also issued estimates for Stryker’s Q3 2025 earnings at $3.26 EPS, Q4 2025 earnings at $4.23 EPS and FY2025 earnings at $13.53 EPS.

Several other equities research analysts have also recently commented on the company. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Robert W. Baird upped their target price on shares of Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Evercore ISI boosted their price target on Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Needham & Company LLC boosted their target price on Stryker from $393.00 to $409.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Stock Up 1.1 %

Shares of Stryker stock opened at $389.88 on Thursday. The company has a market capitalization of $148.63 billion, a P/E ratio of 41.79, a price-to-earnings-growth ratio of 2.93 and a beta of 0.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The business has a 50-day moving average of $365.91 and a two-hundred day moving average of $348.95. Stryker has a 1 year low of $285.79 and a 1 year high of $398.20.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.46 EPS.

Hedge Funds Weigh In On Stryker

A number of institutional investors have recently bought and sold shares of the stock. Unigestion Holding SA bought a new stake in shares of Stryker during the third quarter valued at approximately $580,000. Sunbelt Securities Inc. raised its stake in Stryker by 25.6% during the third quarter. Sunbelt Securities Inc. now owns 501 shares of the medical technology company’s stock valued at $181,000 after buying an additional 102 shares during the last quarter. Toronto Dominion Bank raised its position in shares of Stryker by 2.3% in the 3rd quarter. Toronto Dominion Bank now owns 173,965 shares of the medical technology company’s stock worth $62,847,000 after purchasing an additional 3,855 shares during the last quarter. Neo Ivy Capital Management purchased a new position in Stryker in the third quarter worth about $966,000. Finally, Wilson & Boucher Capital Management LLC increased its position in shares of Stryker by 0.6% during the third quarter. Wilson & Boucher Capital Management LLC now owns 8,770 shares of the medical technology company’s stock valued at $3,168,000 after acquiring an additional 50 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Viju Menon sold 600 shares of Stryker stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the transaction, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. The trade was a 6.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the transaction, the vice president now directly owns 10,042 shares in the company, valued at $3,715,540. This trade represents a 17.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,381 shares of company stock worth $24,825,275 in the last ninety days. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.